US EditionResearch reveals how psychedelics reshape communication between the brain and immune system
- In April 2025, Dr. Michael Wheeler and his team published research in Nature showing psychedelics reshape brain-immune communication to reduce fear and stress responses.
- This research built on the idea that mental health disorders involve brain-body immune loops, which had been previously overlooked in focusing only on brain behavior.
- The team identified how chronic stress triggers inflammatory cascades in the amygdala that increase fear behaviors, and showed psychedelics like psilocybin block immune cell accumulation to reverse this process.
- Dr. Wheeler emphasized that these findings open up new avenues for therapeutic approaches addressing inflammation-related illnesses, including mental health challenges such as anxiety and depression.
- These findings suggest psychedelics may transform neuropsychiatric and inflammatory disorder treatments, though further research and clinical trials remain necessary to confirm safety and efficacy.
19 Articles
19 Articles
A dose of psilocybin stirred the brain of a barely conscious woman
A new case report published in Clinical Neurophysiology describes the first known administration of psilocybin—a psychedelic compound found in certain mushrooms—to a woman in a minimally conscious state. Although there was no improvement on standard clinical assessments, the patient exhibited new spontaneous behaviors and a notable increase in brain complexity, suggesting altered internal experience. The findings raise the possibility that psych…
Research reveals how psychedelics reshape communication between the brain and immune system
In a compelling Genomic Press interview published today, rising scientific star Dr. Michael Wheeler unveils revolutionary findings about how psychedelics reshape communication between the brain and immune system, potentially transforming treatments for psychiatric disorders and inflammatory diseases alike.
Psilocybin in Serious Illness: James Downar, Ali John Zarrabi and Margaret Ross
SummaryTranscriptCMESummary We’ve covered psychedelics on the podcast before—first in 2019 with Ira Byock, where we explored their potential role in medicine, and then again in 2023 with Stacy Fischer, Brian Anderson, and Theora Cimino, focusing on the reasons to approach psychedelic use in patients with caution. In today’s episode, we’re taking a closer look at the current state of the science around one specific psychedelic: psilocybin…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
